ANP: MHRA approval for ATL1102 Phase IIb DMD clinical trial in UK
ANTISENSE THERAPEUTICS LIMITED ๐ ๐ ๐
- MHRA approval granted for Phase IIb trial of ATL1102 in DMD patients in the UK.
- Regulatory approvals obtained in all four countries (UK, Turkey, Bulgaria, and Australia) for the trial.
- Three patients have received their first dose and further UK clinical sites to open for patient enrollment during Q3 2023.

2023-06-27 15:46:00